עיינה פארמה קיבלה את אישור ה-FDA לשיווק בארה”ב של תרופה ננוטכנולוגית לטיפול בסרטן
החברה הישראלית והשותף האסטרטגי פאדאגיס ערוכים להשקה מסחרית של התרופה בארה"ב חברת עיינה פארמה, הפועלת מירושלים, הודיעה היום כי תרופת ה- Liposomal HCl-Doxorubicin
SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases
בחזית המאבק בסרטן: פיתוח שיסייע למערכת החיסון לזהות ולתקוף גידולים חמקמקים
Nectin Therapeutics, חברה ישראלית המפתחת טיפולים ביולוגיים חדשניים בתחום האימונו-אונקולוגיה, השלימה גיוס של 15 מיליון דולר בסבב B. את הגיוס הובילה Velocity aMoon של קרן אמון, עם השקעה אישית נוספת של מריוס נכט, ובהשתתפות אינטגרה הולדינגס.
aMoon Fund Leads Investment Round in Nectin Therapeutics with Initial Closing of $6M, Total Investment Expected to Reach $15M
Nectin will use the funding for further development of its next-generation immuno-oncology antibodies that help the immune system fight cancer
EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
First academic BRIDGE Partnership in Israel aims to translate early-stage research from the Hebrew University (“HU”) of Jerusalem into industrial drug development projects
Atox Bio Closes $30 Million Investment
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing
Temasek Leads $25 Million Investment Round in Integra Holdings
Funds will Contribute to Expansion and Development of Integra’s Portfolio, Bringing Hebrew University’s Life Science Innovations to Market
Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou Pharmaceutical Group
Jerusalem, Israel, December 8, 2014 - Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem
Avraham Pharmaceuticals Raises $4.5 Million in Additional Investment Led by Yissum
The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016
Atox Bio Closes $23 Million Investment
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections
Tiltan Pharma Raises $1.5 Million
The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer
Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”
Findings published in the Journal of Infectious Diseases
Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim
Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer
White Plains Hospital is the first U.S. site
to offer this innovative treatment to cancer patients
Yissum Announces Formation of Integra Holdings, a Biopharmaceutical Holding Company
Integra Holdings closes U.S. $ 7.0 million private financing
Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012
Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer
Jerusalem Israel - February 13, 2012 - Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.
Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals
Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company
Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.
Rehovot Israel - October 13, 2010 - Atox Bio Inc. today announced that it has raised $2.1 million to advance the development of AB103, a clinical stage therapeutic being developed for the treatment of severe bacterial infections and sepsis.
Atox Bio, a Spin-Off of Yissum, Announces Dosing of First Subject in Phase 1 study of AB103, a Novel Immunomodulator for the Treatment of Severe Bacterial Infections and Sepsis
Rehovot Israel - September 15, 2010 - Atox Bio, a Spin-Off of Yissum, today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103